Drug-Coated Balloon Only Strategy After Recanalization of Chronic Total Coronary Occlusions
Not yet recruitingNot applicableNCT07817719
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic total occlusions (CTO) of the coronary arteries are usually treated with drug-eluting stents (DES) after successful recanalization. Permanent metallic scaffolds carry recognized long-term limitations, including late malapposition, very late stent thrombosis, impairment of positive vascular remodeling, and edge restenosis after geographic miss. Drug-coated balloons (DCB) deliver an antiproliferative agent to the vessel wall without leaving a permanent implant, and may be particularly attractive in long, fibrocalcific recanalized CTO segments. NoTrace-CTO is a prospective, single-center, investigator-initiated, single-arm pilot study evaluating an exclusive DCB-only strategy, with no stent implantation, after successful CTO recanalization. Thirty-eight patients are planned, to yield thirty evaluable patients with paired angiographic follow-up. The primary endpoint is in-balloon late lumen loss at nine months, measured by quantitative coronary angiography (QCA) and tested against a pre-specified performance goal of 0.50 mm derived from a pooled contemporary second-generation DES benchmark. The proportion of lesions completing the DCB-only strategy without bailout stenting is reported descriptively alongside it. Serial intravascular ultrasound (IVUS) performed at baseline, immediately after DCB delivery and at nine months is the mechanistic centerpiece of the study, assessing vascular remodeling directly. Secondary assessments include quantitative flow ratio (QFR), Seattle Angina Questionnaire (SAQ) scores, binary restenosis, reocclusion, target lesion and target vessel revascularization, major adverse cardiovascular events (MACE), bleeding classified by the Bleeding Academic Research Consortium (BARC) criteria, and acute kidney injury defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. The study is not powered for comparative clinical superiority or non-inferiority against DES; its findings are hypothesis-generating and intended to inform…
Study details
- Official title
- NoTrace-CTO: Exclusive Drug-Coated Balloon Use After Recanalization of Chronic Total Coronary Occlusions - A Prospective, Single-Center, Single-Arm Study With Paired Quantitative Coronary Angiography and Serial Intravascular Ultrasound
- Conditions
- Angina (Stable)
- Coronary Occlusion
- Coronary Artery Disease
- Chronic Total Occlusion
- Interventions
- Device: Paclitaxel-coated balloon (AGENT Paclitaxel-Coated PTCA Balloon Catheter)
- Procedure: Serial intravascular ultrasound and protocol-mandated nine-month angiographic reassessment
- Sponsor
- University of Sao Paulo General Hospital
- Collaborators
- Boston Scientific Corporation
- Start date
- 2026-11
- Primary completion
- 2028-02
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Brazil
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18 years or older * Chronic total coronary occlusion (CTO) of more than three months' duration, confirmed by prior angiography or lesion characteristics * Clinical indication for revascularization, defined as limiting angina and/or documented ischemia * Successful CTO recanalization, defined as restoration of Thrombolysis in Myocardial Infarction (TIMI) grade 3 antegrade flow and absence of any flow-limiting dissection * Life expectancy greater than one year * Written informed consent provided Exclusion Criteria: * Acute coronary syndrome or cardiogenic shock at presentation * Flow-limiting dissection (TIMI grade below 3) requiring stent implantation * Left main coronary artery as the CTO target vessel * Reference vessel diameter below 2.0 mm or above 4.0 mm * In-stent chronic total occlusion * Absolute contraindication to dual antiplatelet therapy for the protocol-defined duration of 3 to 6 months * Inability to achieve adequate lesion preparation, defined as absence of flow-limiting or otherwise significant dissection and satisfactory conditions for drug delivery, confirmed by angiography and intravascular ultrasound (IVUS)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07817719